ReviewNature protocols2026
In vivo ultrasound-induced luminescence imaging via trianthracene derivatives nanomaterials.
Review in Nature protocols, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advances in neurotensin receptor 1-targeted molecular probes for tumor molecular imaging and therapy.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Photoluminescence imaging is valuable for elucidating biological processes and diagnosing diseases, but its tissue penetration is limited. We developed an imaging technique that utilizes ultrasound to activate the piezoelectric effect of a molecular probe, transforming ultrasound energy into chemical energy. The chemical energy is then converted into light emission through the chemiluminescence effect, improving penetration depth and overcoming traditional photoluminescence imaging constraints. Here we describe how to build two kinds of ultrasound-induced luminescence imaging systems. We introduce a procedure for the synthesis of trianthracene derivative (TD) nanoparticles with ultrasound-induced luminescence properties. The TDs are converted into water-soluble nanoparticles by a simple nanoprecipitation method. Utilizing the constructed ultrasound-induced luminescence imaging systems, TD nanoparticles can be stimulated to exhibit a luminescence spectrum peaking between 625 and 650 nm. Under optimized ultrasound excitation time and excitation power density parameters, the imaging quality and tissue penetration depth are effectively enhanced. Notably, our procedure enables the detection of both subcutaneous tumor models and challenging deep-tissue orthotopic gliomas. This ultrasound-mediated approach represents an important advancement over conventional photoluminescence imaging methods, enabling high-fidelity in vivo tumor imaging with superior signal quality. Establishment of the ultrasound-induced luminescence imaging systems requires ~2 h, the synthesis of TD molecules requires ~4 d, nanoparticle preparation requires ~1 d, ex vivo characterization requires ~1 d, investigation of the ultrasound-induced luminescence of TD nanoparticles requires ~3 d and ultrasound-induced luminescence imaging takes ~1 d. These steps can be performed by operators trained in chemical synthesis, nanomaterial synthesis standards and qualified in relevant animal experiments.
Indexed as
Identifiers
40993231What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.